Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
65
Frequently Asked Questions
What is Market Cap of Spyre Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Spyre Therapeutics Inc. market cap is $980.91M.
What is the 52-week high for Spyre Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Spyre Therapeutics Inc. 52 week high is $40.26 as of September 28, 2025.
What is the 52-week low for Spyre Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Spyre Therapeutics Inc. 52 week low is $10.91 as of September 28, 2025.
What is Spyre Therapeutics Inc. stock price today?
Spyre Therapeutics Inc. stock price today is $16.24.
What was Spyre Therapeutics Inc. stock price yesterday?
Spyre Therapeutics Inc. stock price yesterday was $15.61.
What is the PE ratio of Spyre Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Spyre Therapeutics Inc.’s P/E ratio is -5.33.
What is the Price-to-Book ratio of Spyre Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Spyre Therapeutics Inc. P/B ratio is 2.1641.
What is the 50-day moving average of Spyre Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Spyre Therapeutics Inc. 50-day moving average is $16.40.
How many employess does Spyre Therapeutics Inc. has?
